Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Company news
>
2024
Company news, 2024
#BIO2024!
#BIO2024!
Thank you to everyone who visited us at the ChemDiv, Inc. booth in the California Pavilion.
ChemDiv, Inc. is coming to #BIO2024!
ChemDiv, Inc. is coming to #BIO2024! Join us at the California Pavilion booth #2625 or connect with us through the Partnering System.
ChemDiv to Participate in the EF Hutton Annual Global Conference
ChemDiv, Inc, announced today that Bill Farley, CEO, will participate in the EF Hutton Annual Global Conference (https://efhutton.com/conference/). The conference is being held in person at Th...
Team ChemDiv, Inc. at AACR 2024, San Diego!
Last week, our team had the incredible opportunity to attend the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.
AACR 2024
Excited for AACR 2024, we invite you to meet our executive team, led by CEO Bill Farley.
The Drug Discovery Chemistry conference in San Diego.
Last week, our ChemDiv team, Michael Nyman, Roman Timakhov, and Aleksandra Khotimchenko, had the incredible opportunity to attend the Drug Discovery Chemistry conference in sunny San Diego.
Meet ChemDiv at Drug Discovery Chemistry in San Diego, April 1-4.
We're thrilled to announce that our team members, Roman Timakhov and Aleksandra Khotimchenko, will be attending the Drug Discovery Chemistry in San Diego, April 1-4.
Meet ChemDiv at the 42nd Annual JPM Healthcare Conference in San Francisco
42nd Annual JPM Healthcare Conference, held from January 8th to 11th, 2024, in San Francisco, CA.
ChemDiv Marks a Milestone
ChemDiv Marks a Milestone as Orionis Biosciences' Novel Immunotherapy Enters Phase I Clinical Trials
1